Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis has appointed Miguel Martin as its new Chief Executive Officer, effective immediately. Martin, who has extensive experience in consumer goods and regulated industries, previously served as Aurora's Chief Commercial Officer. He replaces Michael Singer, who was Interim CEO since February 2020 and will continue as Executive Chairman. Martin expressed confidence in Aurora's potential, citing its deep industry knowledge and commitment to quality as key strengths. The leadership change aims to drive sustainable growth and profitability for the company.
Aurora Cannabis announced the appointment of Miguel Martin as Chief Commercial Officer, effective immediately, replacing Darren Karasiuk. Martin, previously President of Aurora USA and CEO of Reliva, brings over 25 years of experience in consumer packaged goods. His role aims to enhance Aurora's revenues and brand strength in global markets. Executive Chairman Michael Singer highlighted Martin's proven track record in regulated industries, aligning with Aurora's commitment to profitability and excellence in sales and marketing.
Aurora Cannabis (ACB) has announced significant updates on its Business Transformation Plan, including an SG&A run rate target of approximately $42 million for Q1 2021. The company is focused on enhancing margins and profitability through personnel restructuring, with a 25% reduction in SG&A staff and a 30% reduction in production staff. Additionally, Aurora is consolidating its production facilities to improve efficiency and expects to report a positive adjusted EBITDA for Q1 2021. However, the company anticipates up to $60 million in impairment charges related to facility closures.